GW Pharma Shares Double Following Positive Epidiolex Trial
Shares of GW Pharmaceuticals PLC-ADR GWPH 1.12% are up nearly 120 percent in early Monday trading after the company announced positive Phase III data on Epidiolex. The study found that the drug significantly reduced seizures in children suffering from Dravet Syndrome, a condition for which there are currently no FDA-approved treatments.